It is the study to compare non surgical treatment modality for gastroduodenal obstruction

NOVEL NON SURGICAL TREATMENT MODALITY FOR GASTRODUODENAL OUTLET OBSTRUCTION - RANDOMIZED CONTROLLED TRIAL

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/07/026501

Enrollment

Registered

2020-07-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K318- Other specified diseases of stomach and duodenum

Interventions

Intervention1: Misoprostol (400 mg TDS) Plus Pantoprazole (40 mg BD: misoprostol (400 mg TDS) plus pantoprazole 40 mg BD, Oral, For 14 Weeks with CRE dilatation Control Intervention1: misoprostol (40

Eligibility

Inclusion criteria

Inclusion criteria: 1- Patients aged more than 18 years 2- With benign gastroduodenal stricture related to NSAIDs, opiods, caustic and peptic

Exclusion criteria

Exclusion criteria: 1- Previous poor compliance with pharmacologic treatment. 2- Refused to give consent for participation in study 3- Contraindication for misoprostol therapy 4- Patient with other causes of benign GOO such as chronic pancreatitis, Crohnâ??s and tuberculosis and fibrotic(healed) stricture will also excluded. 5- Patient who continue to take NSAIDs, opiods and smoke will also excluded.

Design outcomes

Primary

Measure	Time frame
1-Symptoms resolution ( heart burn, vomiting, abdomen pain and post prandial fullness) 2-Need for CRE dilatataion( number of CRE dilatation session) 3-Need for surgeryTimepoint: 14 weeks	—

Secondary

Measure	Time frame
Improvement in nutritional status (Hemoglobin, serum albumin, bodyweightTimepoint: 14 weeks	—

Countries

India

Contacts

Public ContactDr Gireesh kumar Dhaked

SMS medical college, jaipur

pa894@yahoo.co.in9829966420

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026